Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 7/20 | 0.56 |
| ▸ | UBE2M | P61081 | 1/20 | 0.48 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | AGER | Q15109 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20857039 | 0.85 | CYP2C9 (0.55) | OPRM1CHRM2CHRM3CCR5KCNH2 | |
| SCHEMBL23175993 | 0.82 | AGER (0.63) | OPRM1CHRM2CHRM3AGERLMNA | |
| SCHEMBL20857036 | 0.82 | AVPR1A (0.48) | OPRM1CCR5KCNH2 | |
| SCHEMBL20857058 | 0.82 | KMT2A (0.48) | OPRM1CHRM2CHRM3CCR5KCNH2 | |
| SCHEMBL20857066 | 0.81 | HTT (0.50) | OPRM1UBE2MDCUN1D1CHRM2CHRM3 | |
| SCHEMBL2936216 | 0.81 | OPRM1 (0.58) | OPRM1CHRM2CHRM3TMEM97AGER | |
| SCHEMBL20857072 | 0.79 | MAPT (0.47) | OPRM1CHRM2CHRM3CCR5KCNH2 | |
| SCHEMBL20857067 | 0.78 | RBP4 (0.48) | OPRM1 | |
| SCHEMBL7280301 | 0.76 | LTA4H (0.63) | OPRM1UBE2MDCUN1D1RORC | |
| SCHEMBL22387506 | 0.76 | SLC6A2 (0.51) | OPRM1DCUN1D1KCNH2AGER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200278355-A1 | CONJUGATED PROTEINS AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200278355-A1 | CONJUGATED PROTEINS AND USES THEREOF | SCRIPPS RESEARCH INST (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3688472-A1 | CONJUGATED PROTEINS AND USES THEREOF | The Scripps Research Institute (US) | 2020-08-05 | — | — | EP | disclosed |
| WO-2019067741-A1 | CONJUGATED PROTEINS AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200278355-A1 | CONJUGATED PROTEINS AND USES THEREOF | KEAP1, GSTK1, GSTM2 | OPRM1 1992/4885UBE2M 399/4885DCUN1D1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.